Overview

To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis

Status:
Recruiting

Trial end date:
2024-05-20

Target enrollment:

Participant gender:

Summary

Japanese patients with moderate or severe active ulcerative colitis as a subject when ozanimod 0.46 mg or 0.92 mg is orally administered is evaluated about dose response, efficacy and safety with placebo as a control.

Phase:

Phase 3

Details

Lead Sponsor:

Celgene

Treatments:

Ozanimod